Assess whether pediatric studies are necessary or waivable (9b9115)

Situation

In a safety team sitting on a new disproportionate signal, RWE protocol that may not meet regulator expectations is the evidence after an FAERS cluster in a demographic the trials under-enrolled. 505(b)(2) development lead has to pick Pediatric studies are necessary or Waivable for this Pharma & Life Sciences Pharmacovigilance close using RWE protocol that may not meet regulator expectations.

Decision

505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose Pediatric studies are necessary / Waivable using RWE protocol that may not meet regulator expectations after an FAERS cluster in a demographic the trials under-enrolled.

Hypotheses to test

• RWE protocol that may not meet regulator expectations reads as Pediatric studies are necessary once an FAERS cluster in a demographic the trials under-enrolled is lined up to the same Pharma & Life Sciences population.
• RWE protocol that may not meet regulator expectations is closer to Waivable after an FAERS cluster in a demographic the trials under-enrolled; Pediatric studies are necessary would over-claim this Pharmacovigilance extract.
• A dual reading is still live in RWE protocol that may not meet regulator expectations for 505(b)(2) development lead in a safety team sitting on a new disproportionate signal.
• RWE protocol that may not meet regulator expectations is missing the fact 505(b)(2) development lead needs after an FAERS cluster in a demographic the trials under-enrolled; stop this Pharma & Life Sciences close.

Analysis required

• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after an FAERS cluster in a demographic the trials under-enrolled.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Pharmacovigilance file, read RWE protocol that may not meet regulator expectations against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move pediatric studies are necessary for 505(b)(2) development lead.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / Pharmacovigilance packet (RWE protocol that may not meet regulator expectations after an FAERS cluster in a demographic the trials under-enrolled). Lead with the Pharma & Life Sciences option RWE protocol that may not meet regulator expectations can support after an FAERS cluster in a demographic the trials under-enrolled, then the two facts that force it, then the Monday action for 505(b)(2) development lead in a safety team sitting on a new disproportionate signal.